ArticleNeuro-oncology practice2026
Healthcare utilization and 30-day in-hospital costs following brain tumor surgery: A single-center, retrospective cohort study.
Article in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain tumors cause more than 248 000 deaths annually, and their incidence continues to rise. Despite medical advances, outcomes have improved marginally, and the associated economic burden is substantial. European spending was estimated at €37.8 billion in 2019. Although several cost drivers have been identified, robust and methodologically sound cost evaluations remain limited. This study aimed to quantify 30-day in-hospital healthcare consumption and identify cost drivers in brain tumor surgery. Methods: Adult patients undergoing brain tumor surgery in 2023 at a single regional referral center were retrospectively analyzed. The primary outcome was total 30-day in-hospital costs, calculated using a bottom-up microcosting approach. Univariable and multivariable analyses were performed to identify key cost drivers. Results: A total of 322 patients (mean age 61 years; 51.2% female) were included in this study. Median length of stay (LOS) was 3 days (interquartile range; 2-6), and mean in-hospital costs were € 6988 per patient (SD ± € 4273). Tumor pathology was associated with significantly increased surgical costs ( Conclusions: Thirty-day in-hospital costs following brain tumor surgery are substantial, mainly driven by operative and hospitalization factors. Identifying modifiable cost determinants is essential for developing targeted interventions to improve efficiency and optimize resource utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.